When we come down with the flu, we might think the worst is over after a week of a sore throat and body aches. But such viral infections may have lasting, unsee

Using special nutrients and a good diet is the best way to deal with signs of dementia. Ginkgo Biloba has been used for centuries and it still has been proven to be one of the best nutrients to improve brain function. Find out why.

Most Americans are deficient in zinc. Zinc is used in numerous chemical activities in the body. If you are deficient in zinc, you will have a lot of physical and mental problems. Learn how and why you need more zinc in your body.

A location-tracking app to alert caregivers when a loved one wanders from a defined safe-zone—especially important during covid-19.

Kyoto University researchers said the vaccine for Alzheimer’s was effective and was also shown to have zero side effects observed in the mice.

The post New Alzheimer’s Nasal Spray Shown to Reduce Proteins Which Cause the Disease in Mice appeared first on Good News Network.

In recent years there has been a burgeoning interest in the use of computational methods to distinguish between elicited speech samples produced by patients with dementia, and those from healthy controls. The difference between perplexity estimates from two neural language models (LMs) - one trained on transcripts of speech produced by healthy participants and the other trained on transcripts from patients with dementia - as a single feature for diagnostic classification of unseen transcripts has been shown to produce state-of-the-art performance. However, little is known about why this approach is effective, and on account of the lack of case/control matching in the most widely-used evaluation set of transcripts (DementiaBank), it is unclear if these approaches are truly diagnostic, or are sensitive to other variables. In this paper, we interrogate neural LMs trained on participants with and without dementia using synthetic narratives previously developed to simulate progressive semantic dementia by manipulating lexical frequency. We find that perplexity of neural LMs is strongly and differentially associated with lexical frequency, and that a mixture model resulting from interpolating control and dementia LMs improves upon the current state-of-the-art for models trained on transcript text exclusively.

The portable, wearable, proximal Alzheimer's disease treatment invention is based upon creating an RF field of particular frequencies and intensities that are applied to the patient's head. To accomplish the aforementioned disease treatment functionality, a system was invented comprising a network of antennas connected to an RF generator via a feedline connector. The invention also provides methods for using measurements to monitor and manage the effectiveness of an ongoing disease treatment regimen, and databases which contain information about measurements, variables, and their relationships to clinical outcome.

Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, nutraceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor. The system can utilize a pump, pressurized reservoir, a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with porous membranes or micro-fabricated structures.

In sporadic Alzheimer's disease, neurofibrillary lesion formation is preceded by extensive post-translational modification of the microtubule associated protein tau. Immunoassays have been developed recently that detect tau in biological specimens, thus providing a means for pre-mortem diagnosis of Alzheimer's disease, which has remained elusive. These assays have been improved by the analysis of relevant post-translational modifications, such as phosphorylation, however opportunity for improvement remains. The present invention addresses this issue by disclosing synthetic methylated peptides derived from the tau protein of paired helical filaments and non-diseased control brain. Alzheimer's disease specificity is provided by the presence or absence of methyl moieties on lysine residues and differences between mono-, di-, and tri-methylation. The methylated peptide is useful as an antigen and a binding partner for identifying compounds that interact with the peptide and the methylated tau protein, including antibodies that can distinguish non-diseased brain from that affected by Alzheimer's disease. The resulting antibodies are useful diagnostically and therapeutically. The compounds that specifically bind to methylated tau proteins are useful for eliminating abnormally methylated tau.

Representatives from The Alzheimer's Association - Western North Carolina Chapter made a return to The Friday Feature to talk about a community forum event in the region, while reminding anyone dealing with a loved one who has the Alzheimer's disease, that they want to provide support. Guest was Denise Young- Program Manager of the association. This conversation was first presented on Feb. 21, 2020. Posted by Host and Producer of WNCW's Friday Feature Interview of the Week- Paul Foster, Senior Producer, News Director, and Morning Edition Regional Host

Exame poderá detectar a doença na fase inicial. Pesquisadores da Faculdade de Medicina Osteopática da Universidade de Rowan, nos Estados Unidos, afirmam que estão perto de desenvolver um exame de sangue para detectar Alzheimer com precisão, o que dar...

The post Teste de sangue para detectar Alzheimer está próximo da realidade appeared first on Saúde Próspera.

(University of Southampton) Scientists have published highly detailed images of lab-grown neurons using Extreme Ultraviolet radiation that could aid the analysis of neurodegenerative diseases.

¹⁸F-PI-2620 is a positron emission tomography (PET) tracer with high binding affinity for aggregated tau, a key pathologic feature of Alzheimer’s disease (AD) and other neurodegenerative disorders. Preclinically, ¹⁸F-PI-2620 binds to both, 3R and 4R tau isoforms. The purpose of this first-in-human study was to evaluate the ability of ¹⁸F-PI-2620 to detect tau pathology in AD patients using PET imaging, as well as to assess its safety and tolerability of this new tau PET tracer. Methods: Participants with clinical diagnosis of probable AD and healthy controls (HC) underwent dynamic ¹⁸F-PI-2620 PET imaging for 180 min. ¹⁸F-PI-2620 binding was assessed visually and quantitatively using Distribution Volume Ratios (DVR) estimated from non-invasive tracer kinetics and standardized uptake value ratios (SUVR) measured at different time points post-injection (p.i.) with the cerebellar cortex as the reference region. Time-activity curves and SUVR were assessed in AD and HC, as well as DVR and SUVR correlations and effect size (Cohen’s d) over time. Results: ¹⁸F-PI-2620 showed peak brain uptake around 5 min p.i. and fast wash-out in non-target regions. In AD subjects, focal asymmetric uptake was evident in temporal and parietal lobes, precuneus, and posterior cingulate cortex. DVR and SUVR in these regions were significantly higher in AD compared to HC. Very low background signal was observed in HC. ¹⁸F-PI-2620 administration was safe and well tolerated. SUVR time activity curves in most regions and subjects achieved a secular equilibrium after 40 min p.i.. A strong correlation (R² > 0.93) was found between non-invasive DVR and SUVR for all imaging windows starting >30 min p.i.. Similar effect sizes between AD and HC groups were obtained across the different imaging windows. ¹⁸F-PI-2620 uptake in neocortical regions was significantly correlated with the degree of cognitive impairment. Conclusion: Initial clinical data obtained in AD and HC demonstrate the high image quality with excellent signal-to-noise of ¹⁸F-PI-2620 PET for imaging tau deposition in AD subjects. Non-invasive quantification using DVR and SUVR for 30 min imaging windows between 30-90 min p.i., e.g. 45-75 min, provides robust and significant discrimination between AD and HC subjects. ¹⁸F-PI-2620 uptake in expected regions is highly correlated to neurocognitive performance.

It was hypothesized that the brain β-amyloid buildup curve plateaus at an early symptomatic Alzheimer's disease (AD) stage. Atrophy-related partial volume effects (PVEs) degrade signal in hot-spot imaging techniques, such as amyloid positron emission tomography (PET). This longitudinal analysis of amyloid-sensitive PET data investigated the shape of the β-amyloid curve in AD applying PVE correction (PVEC). We analyzed baseline and 2-year follow-up data of 216 symptomatic individuals on the AD continuum (positive amyloid status) enrolled in Alzheimer's Disease Neuroimaging Initiative (17 AD dementia, 199 mild cognitive impairment), including 18F-florbetapir PET, magnetic resonance imaging and mini mental state examination (MMSE) scores. For PVEC, the modified Müller-Gärtner method was performed. Compared to non-PVE-corrected data, PVE-corrected data yielded significantly higher regional and composite standardized uptake value ratio (SUVR) changes over time (P=0.0002 for composite SUVRs). Longitudinal SUVR changes in relation to MMSE decreases showed a significantly higher slope of the regression line in the PVE-corrected as compared to the non-PVE-corrected PET data (F=7.1, P=0.008). These PVEC results indicate that the β-amyloid buildup curve does not plateau at an early symptomatic disease stage. A further evaluation of the impact of PVEC on the in-vivo characterization of time-dependent AD pathology, including the reliable assessment and comparison of other amyloid tracers, is warranted.

The present study examined the predictive values of amyloid PET, ¹⁸F-FDG PET, and nonimaging predictors (alone and in combination) for development of Alzheimer dementia (AD) in a large population of patients with mild cognitive impairment (MCI). Methods: The study included 319 patients with MCI from the Alzheimer Disease Neuroimaging Initiative database. In a derivation dataset (n = 159), the following Cox proportional-hazards models were constructed, each adjusted for age and sex: amyloid PET using ¹⁸F-florbetapir (pattern expression score of an amyloid-β AD conversion–related pattern, constructed by principle-components analysis); ¹⁸F-FDG PET (pattern expression score of a previously defined ¹⁸F-FDG–based AD conversion–related pattern, constructed by principle-components analysis); nonimaging (functional activities questionnaire, apolipoprotein E, and mini-mental state examination score); ¹⁸F-FDG PET + amyloid PET; amyloid PET + nonimaging; ¹⁸F-FDG PET + nonimaging; and amyloid PET + ¹⁸F-FDG PET + nonimaging. In a second step, the results of Cox regressions were applied to a validation dataset (n = 160) to stratify subjects according to the predicted conversion risk. Results: On the basis of the independent validation dataset, the ¹⁸F-FDG PET model yielded a significantly higher predictive value than the amyloid PET model. However, both were inferior to the nonimaging model and were significantly improved by the addition of nonimaging variables. The best prediction accuracy was reached by combining ¹⁸F-FDG PET, amyloid PET, and nonimaging variables. The combined model yielded 5-y free-of-conversion rates of 100%, 64%, and 24% for the low-, medium- and high-risk groups, respectively. Conclusion: ¹⁸F-FDG PET, amyloid PET, and nonimaging variables represent complementary predictors of conversion from MCI to AD. Especially in combination, they enable an accurate stratification of patients according to their conversion risks, which is of great interest for patient care and clinical trials.

Bio-engineered models of the human brain infected with herpes simplex virus-1 develop many of the same characteristics found in Alzheimer's disease, according to a new analysis published by Science Advances.

Alzheimer’s took my wife’s memory and her life and tortured our family. There was nothing we—or medicine—could do to stop it 

-- Read more on ScientificAmerican.com

It is time for a fresh approach to the illness

-- Read more on ScientificAmerican.com

Some nominally high-risk individuals may have a lower chance of developing dementia than once thought

-- Read more on ScientificAmerican.com

Fresh approaches and hopeful clues in the search for novel therapies

-- Read more on ScientificAmerican.com

Research into the brain’s protein-disposal systems, electrical activity and three other areas looks promising

-- Read more on ScientificAmerican.com

Amyloid, the leading target for dementia therapy, faces skepticism after drug failures

-- Read more on ScientificAmerican.com

Being female is a risk factor for Alzheimer’s. Why?

-- Read more on ScientificAmerican.com

Arkaprava Roy, Subhashis Ghosal, Jeffrey Prescott, Kingshuk Roy Choudhury.

Source: The Annals of Applied Statistics, Volume 13, Number 3, 1791--1816.

Abstract:
We study possible relations between Alzheimer’s disease progression and the structure of the connectome which is white matter connecting different regions of the brain. Regression models in covariates including age, gender and disease status for the extent of white matter connecting each pair of regions of the brain are proposed. Subject inhomogeneity is also incorporated in the model through random effects with an unknown distribution. As there is a large number of pairs of regions, we also adopt a dimension reduction technique through graphon ( J. Combin. Theory Ser. B 96 (2006) 933–957) functions which reduces the functions of pairs of regions to functions of regions. The connecting graphon functions are considered unknown but the assumed smoothness allows putting priors of low complexity on these functions. We pursue a nonparametric Bayesian approach by assigning a Dirichlet process scale mixture of zero to mean normal prior on the distributions of the random effects and finite random series of tensor products of B-splines priors on the underlying graphon functions. We develop efficient Markov chain Monte Carlo techniques for drawing samples for the posterior distributions using Hamiltonian Monte Carlo (HMC). The proposed Bayesian method overwhelmingly outperforms a competing method based on ANCOVA models in the simulation setup. The proposed Bayesian approach is applied on a dataset of 100 subjects and 83 brain regions and key regions implicated in the changing connectome are identified.

Randy L. Buckner
Feb 11, 2009; 29:1860-1873
Neurobiology of Disease

Insulin resistance plays a role in obesity. Recently it has been associated with increased risk of AD. Aβ42 and PSEN1 are molecules associated with increased risk of later AD. Patients affected by AD show elevated levels of plasma Aβ42.

Levels of Aβ42 and PSEN1 are significantly elevated in obese adolescents and correlated with the degree of both adiposity and systemic insulin resistance. (Read the full article)

As part of National Alzheimer’s Awareness Month, the Delaware Division of Public Health (DPH) urges Delawareans to make lifestyle adjustments to help reduce their risk factors for Alzheimer’s and dementia.

A study of brain cells in a dish adds to growing evidence that Alzheimer’s disease can be caused by herpes viruses, but antiviral treatment may help stop it

Title: AHA News: Hearing Loss and the Connection to Alzheimer's Disease, Dementia
Category: Health News
Created: 5/6/2020 12:00:00 AM
Last Editorial Review: 5/7/2020 12:00:00 AM

Title: New Finding Could Mark Shift in Alzheimer's Research
Category: Health News
Created: 4/29/2010 8:10:00 AM
Last Editorial Review: 4/29/2010 12:00:00 AM

Title: Fish, Flaxseed May Lower Alzheimer's Risk
Category: Health News
Created: 5/3/2012 11:01:00 AM
Last Editorial Review: 5/3/2012 12:00:00 AM

Title: Alzheimer's Variation May Often Go Unrecognized: Study
Category: Health News
Created: 5/2/2014 9:35:00 AM
Last Editorial Review: 5/2/2014 12:00:00 AM

Title: Trouble With Sense of Direction May Be Linked to Early Alzheimer's: Study
Category: Health News
Created: 4/26/2016 12:00:00 AM
Last Editorial Review: 4/27/2016 12:00:00 AM

Title: Are People With Rosacea at Higher Risk for Alzheimer's?
Category: Health News
Created: 4/28/2016 12:00:00 AM
Last Editorial Review: 4/28/2016 12:00:00 AM

Title: 'Silent' Seizures Tied to Alzheimer's Symptoms
Category: Health News
Created: 5/2/2017 12:00:00 AM
Last Editorial Review: 5/2/2017 12:00:00 AM

Title: Gene Mutation May Speed Alzheimer's Decline
Category: Health News
Created: 5/3/2017 12:00:00 AM
Last Editorial Review: 5/4/2017 12:00:00 AM

Title: Music May Calm the Agitation of Alzheimer's
Category: Health News
Created: 4/30/2018 12:00:00 AM
Last Editorial Review: 5/1/2018 12:00:00 AM

Title: 'Smart Dresser' Might Help Alzheimer's Patients Clothe Themselves
Category: Health News
Created: 5/4/2018 12:00:00 AM
Last Editorial Review: 5/4/2018 12:00:00 AM

Title: Could Alzheimer's Spread Like an Infection Throughout the Brain?
Category: Health News
Created: 5/1/2019 12:00:00 AM
Last Editorial Review: 5/2/2019 12:00:00 AM

Title: U.S. Primary Care Docs Unprepared for Surge in Alzheimer's Cases
Category: Health News
Created: 3/11/2020 12:00:00 AM
Last Editorial Review: 3/11/2020 12:00:00 AM

Title: Could Sleep Apnea Put You at Risk for Alzheimer's?
Category: Health News
Created: 3/25/2020 12:00:00 AM
Last Editorial Review: 3/26/2020 12:00:00 AM

Title: Certain Gene Might Help Shield At-Risk People From Alzheimer's
Category: Health News
Created: 4/13/2020 12:00:00 AM
Last Editorial Review: 4/14/2020 12:00:00 AM

Title: Brain Plaques Signal Alzheimer's Even Before Other Symptoms Emerge: Study
Category: Health News
Created: 4/13/2020 12:00:00 AM
Last Editorial Review: 4/14/2020 12:00:00 AM

A study of brain cells in a dish adds to growing evidence that Alzheimer’s disease can be caused by herpes viruses, but antiviral treatment may help stop it

When tested in brain cells and in a mouse model of Alzheimer's disease, a new compound significantly reduced the number of amyloid plaques in the brain, lessened brain inflammation and diminished other molecular markers of the disease.

Being female is a risk factor for Alzheimer’s. Why?

-- Read more on ScientificAmerican.com

Older adults who consumed large amounts of flavonoid-rich foods were two to four times less likely to develop Alzheimer's disease and related dementias over 20 years compared with people whose intake was low, in a study of 2,800 people.